(OP:AVAI)

Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program

October 07, 2026

Performance

52-Week Range 88.8% below 52-week high

0.0895

0.0852W Low 0.8052W High

1 Week 14.8% below 1-week high

0.091W Low 0.101W High

(AVAI) traded between $0.08 and $0.80 over the past 52 weeks and last traded at $0.09, 88.8% below its 52-week high. Over the past week it ranged between $0.09 and $0.10.

Past 12 Months

-11.4%

-25.4%

-26.7%

-72.3%

-78.2%

-77.5%

1W -$0.01

1M -$0.03

3M -$0.03

6M -$0.23

YTD -$0.32

1Y -$0.31

AVAI was -77.5% over the past year, -72.3% over six months, -78.2% year to date, -11.4% in the last week.

12 Months vs Market

AVAI

-77.5%

DIA

+8.7%

SPY

+8.2%

QQQ

+3.8%

IWM

+10.7%

Over the past 12 months AVAI returned -77.5% versus DIA (Dow) +8.7%, SPY (S&P 500) +8.2%, QQQ (Nasdaq 100) +3.8% and IWM (Russell 2000) +10.7%.

Volume & Liquidity

77.4K

86.3K

90.0K

127.9K

YTD

121.3K

113.5K

AVAI's 3-month average daily volume is 90.0K.

More News

Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape

October 07, 2026

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

September 30, 2026

Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion

September 30, 2026

Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference

September 24, 2026

Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy

September 15, 2026

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

September 08, 2026

From Biotech Insider

Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes

August 12, 2026

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

July 21, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

Five Under-the-Radar Stocks With Catalysts Already in Motion — Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security

April 23, 2026

From World Street Intelligence

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

April 23, 2026

From Equity Insider

Biotech Brief: Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference

April 07, 2026

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

March 18, 2026

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

5 Stocks Sitting on the Right Side of the Biggest Repricing in a Generation

February 18, 2026

THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack

January 26, 2026

From Equity Insider

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

January 23, 2026

From Equity Insider

THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points

January 14, 2026

THE FOUNDATION TRADE: 5 Assets Anchoring the Next Industrial Cycle

December 17, 2025

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

December 16, 2025

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis

December 15, 2025

Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival

December 09, 2025

From Avant Technologies Inc.

Via Business Wire

THE CRITICAL LIST: 5 Stocks Anchoring the New Economy

December 08, 2025